News & Updates

Metformin seems inadequate in reducing the risk of metabolic syndrome (MS) in patients with prostate cancer receiving androgen deprivation therapy (ADT), results of the PRIME study have shown.

In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.

The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.

In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.

Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).

Faecal immunochemical test (FIT) positive result followed by artificial intelligence (AI)–assisted colonoscopy represents the most cost-effective colorectal cancer (CRC) screening strategy in an Asian population, according to a study from the Chinese University of Hong Kong (CUHK).